Skip to main content
. 2019 Nov 28;11(12):1892. doi: 10.3390/cancers11121892

Figure 2.

Figure 2

MRI-response of target lesion in OT101 treated R/R high-grade glioma patients. Depicted are T1-weighted spin echo (SE) post-contrast axial MRI images at baseline vs. post-treatment with OT101 at 433 days post randomization to their respective OT101 dose cohorts. Panels A and B: Unique patient number (UPN) 405-0704 (anaplastic astrocytoma (AA), WHO Grade III) achieved a CR. Panels C and D: UPN4050412 (glioblastoma multiforme (GBM), WHO Grade IV) achieved a PR.